Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference.
The presentation will take place as follows:
- Date: Tuesday, September 12th , 2017
- Time: 5:30 pm EDT (11:30 pm CEST)
- Venue: Lotte New York Palace Hotel in New York, New York
If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at email@example.com .
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
+33 (0)1 44 54 36 64
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212-362-1200
Media Relations (U.S.)
Financial Communication (France)
Emmanuel Huynh, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NY-GTIS-PARTNERS20.9.2018 16:26 | pressemeddelelse
GTIS Partners Grabs Top Spots in Prestigious GRESB Sustainability Ranking
NY-MEDICREA20.9.2018 15:09 | pressemeddelelse
Medicrea Announces Eurospine 2018 Presence and Highlights a Recently Published Study Validating Its Predictive Modelling Approach for AIS Patients
SEOUL-SEMICONDUCTOR20.9.2018 15:02 | pressemeddelelse
Seoul Semiconductor Wins LED Bulb Litigation and Pursuit of Further Enforcement Actions against LED Lighting Retailers
BUSAN-METROPOLITAN-CITY20.9.2018 13:02 | pressemeddelelse
2018 Busan One Asia Festival to Take Place October 20-28
I4MS20.9.2018 12:32 | pressemeddelelse
L4MS Launches Its First Open Call for Cross-Border Application Experiments
CA-UPHOLD20.9.2018 12:02 | pressemeddelelse
Uphold Makes Cred’s LBA Tokens Available For Purchase in 170+ Countries
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum